Tepmetko Drug Interactions

P-gp substrates: Tepotinib can inhibit the transport of sensitive substrates of P-gp (see Pharmacology: Pharmacokinetics under Actions). Concomitant use of TEPMETKO increases the concentration of P-gp substrates, which may increase the incidence and severity of adverse reactions of these substrates. Avoid concomitant use of TEPMETKO with certain P-gp substrates where minimal concentration changes may lead to serious or life-threatening toxicities. If concomitant use is unavoidable, reduce the P-gp substrate dosage if recommended in its approved product labeling.
BCRP substrates: Tepotinib can inhibit the transport of sensitive substrates of the breast cancer resistance protein (BCRP) (see Pharmacology: Pharmacokinetics under Actions). Monitoring of the clinical effects of sensitive BCRP substrates is recommended during co-administration with TEPMETKO.
Metformin: Based on in vitro data, tepotinib or its metabolite may have the potential to alter the exposure to co-administered metformin in humans through inhibition of metformin's renal excretion or hepatic uptake mediated via OCT1 and 2 and MATE1 and 2 (see Pharmacology: Pharmacokinetics under Actions). Monitoring of the clinical effects of metformin is recommended during co-administration with TEPMETKO.